Anti-MDA5+ dermatomyositis has a wider spectrum of manifestations than previously
thought. A high index of suspicion is needed not to miss atypical presentations. In the setting …

Update on dermatomyositis : Current Opinion in Neurology Update on dermatomyositis :
Current Opinion in Neurology Log in or Register Subscribe to journalSubscribe Get new …

As treatment of refractory idiopathic inflammatory myopathies (IIM) has been challenging,
there is growing interest in assessing new therapies that target various pathways implicated …

Objectives To evaluate the efficacy and safety of tofacitinib in treatment-refractory
inflammatory myositis in a real-world clinical setting. Methods All patients with refractory …

Several new therapies for MDA5-DM patients have emerged, although the optimal use of
those therapies is still unknown. Further research and evidence accumulation will be …

Keywords: melanoma differentiation-associated protein 5; prophylaxis; rapidly progressive
interstitial lung disease EN melanoma differentiation-associated protein 5 prophylaxis …

Objective Anti‐MDA5 antibody‐positive dermatomyositis (DM) is a rare clinical autoimmune
disease, and anti‐MDA5‐positive DM with interstitial lung disease (ILD) is the most …

Background: Interstitial lung disease (ILD) is a common extra-muscular manifestation of
idiopathic inflammatory myopathies (IIMs), often associated with a poorer prognosis and …

Anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis (anti-
MDA5-DM) is frequently complicated by progressive interstitial lung disease (ILD), the …

We discuss a case of a 48-year-old female with anti-PL-12 anti-synthetase syndrome. She
presented with dermatitis and myositis and developed rapidly progressive interstitial lung …